Halozyme upsizes and prices $625M convertible notes due 2028, conversion premium ~30%

HALOZYME THERAPEUTICS, INC.

$625M aggregate principal; initial purchasers have option for additional $95M.
1.00% annual interest rate; conversion price ~$56.02/share, 30% above $43.09 close.
Use of proceeds: ~$77.6M to exchange existing 2024 notes, up to $200M for share repurchases, $250M term loan repayment.
Entered capped call transactions with initial cap price ~$75.41/share to reduce dilution.
Expects to close offering on August 18, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.